Corvus Pharmaceuticals released Phase I data for soquelitinib, an oral ITK inhibitor, showing robust clinical activity in moderate‑to‑severe atopic dermatitis (AD). The cohort update demonstrated deepening responses over eight weeks, including activity in patients previously treated with systemic therapies and biologics, prompting a dramatic share rally. The results support Corvus’ move to mid‑stage trials and raise interest in ITK inhibition as an oral alternative to injectable biologics. Analysts flagged the potential for broader use in immune/inflammatory diseases if larger trials confirm safety and efficacy.